GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Cyclically Adjusted Price-to-FCF

AEterna Zentaris (AEterna Zentaris) Cyclically Adjusted Price-to-FCF : (As of Apr. 29, 2024)


View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


AEterna Zentaris Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AEterna Zentaris's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Cyclically Adjusted Price-to-FCF Chart

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AEterna Zentaris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AEterna Zentaris's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, AEterna Zentaris's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Cyclically Adjusted Price-to-FCF falls into.



AEterna Zentaris Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AEterna Zentaris's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, AEterna Zentaris's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.108/125.4675*125.4675
=-1.108

Current CPI (Dec. 2023) = 125.4675.

AEterna Zentaris Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -435.455 98.604 -554.088
201406 -278.652 99.473 -351.469
201409 -273.625 99.394 -345.403
201412 -332.808 98.367 -424.497
201503 -351.207 99.789 -441.581
201506 -184.614 100.500 -230.477
201509 -77.717 100.421 -97.100
201512 -21.144 99.947 -26.543
201603 -22.300 101.054 -27.688
201606 -16.048 102.002 -19.740
201609 -14.352 101.765 -17.695
201612 -17.581 101.449 -21.743
201703 -13.211 102.634 -16.150
201706 -10.469 103.029 -12.749
201709 -8.756 103.345 -10.630
201712 -6.869 103.345 -8.339
201803 25.329 105.004 30.265
201806 -7.260 105.557 -8.629
201809 -3.701 105.636 -4.396
201812 -3.685 105.399 -4.387
201903 -4.568 106.979 -5.357
201906 -3.145 107.690 -3.664
201909 -3.839 107.611 -4.476
201912 -3.688 107.769 -4.294
202003 -2.796 107.927 -3.250
202006 -2.561 108.401 -2.964
202009 -0.798 108.164 -0.926
202012 1.004 108.559 1.160
202103 -0.406 110.298 -0.462
202106 -0.750 111.720 -0.842
202109 -0.308 112.905 -0.342
202112 -0.552 113.774 -0.609
202203 -0.302 117.646 -0.322
202206 -1.007 120.806 -1.046
202209 -0.814 120.648 -0.847
202212 -0.694 120.964 -0.720
202303 -0.837 122.702 -0.856
202306 -0.885 124.203 -0.894
202309 -0.699 125.230 -0.700
202312 -1.108 125.468 -1.108

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AEterna Zentaris  (NAS:AEZS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AEterna Zentaris Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (AEterna Zentaris) Business Description

Industry
Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.